[go: up one dir, main page]

WO2006061650A3 - Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature - Google Patents

Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature Download PDF

Info

Publication number
WO2006061650A3
WO2006061650A3 PCT/GB2005/004764 GB2005004764W WO2006061650A3 WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3 GB 2005004764 W GB2005004764 W GB 2005004764W WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
agents
gpvi
vasculature
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/004764
Other languages
English (en)
Other versions
WO2006061650A2 (fr
Inventor
Goetz Muench
Andreas Bueltmann
Oliver Vimpany Arnold Boucher
Suresh Babubhai Chahwala
Meinrad Gawaz
Martin Ungerer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigen GmbH
Trigen Ltd
Original Assignee
Trigen GmbH
Trigen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/009,106 external-priority patent/US7531178B2/en
Application filed by Trigen GmbH, Trigen Ltd filed Critical Trigen GmbH
Priority to US11/792,857 priority Critical patent/US20090130021A1/en
Priority to EP05849048A priority patent/EP1824979A2/fr
Publication of WO2006061650A2 publication Critical patent/WO2006061650A2/fr
Publication of WO2006061650A3 publication Critical patent/WO2006061650A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des agents interférant avec la liaison de GPVI à divers composants. L'invention concerne également des agents interférant avec l'interaction de GPVI avec la fibronectine et/ou la vironectine ou des séquences de celles-ci. L'invention concerne, en outre, des méthodes de traitement de troubles ou de maladies impliquant une interaction pathologique, dysfonctionnelle ou non pathologique de GPVI avec la fibronectine et/ou la vitronectine. L'invention concerne enfin l'utilisation d'agents dans la prévention ou le traitement de troubles engendrés par l'adhésion et l'agrégation de plaquettes du sang.
PCT/GB2005/004764 2002-06-07 2005-12-12 Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature Ceased WO2006061650A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/792,857 US20090130021A1 (en) 2002-06-07 2005-12-12 Methods, products and uses involving platelets and/or the vasculature
EP05849048A EP1824979A2 (fr) 2004-12-10 2005-12-12 Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/009,106 2004-12-10
US11/009,106 US7531178B2 (en) 2002-06-07 2004-12-10 Immunoadhesin comprising a glycoprotein VI domain
EP05256993 2005-11-11
EP05256993.6 2005-11-11

Publications (2)

Publication Number Publication Date
WO2006061650A2 WO2006061650A2 (fr) 2006-06-15
WO2006061650A3 true WO2006061650A3 (fr) 2006-08-17

Family

ID=36337522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004764 Ceased WO2006061650A2 (fr) 2002-06-07 2005-12-12 Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature

Country Status (2)

Country Link
EP (1) EP1824979A2 (fr)
WO (1) WO2006061650A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007091719A1 (ja) * 2006-02-07 2009-07-02 持田製薬株式会社 抗ｇｐｖｉ抗体の併用療法及び新規医薬用途
US8323905B2 (en) 2006-03-31 2012-12-04 Mochida Pharmaceutical Co., Ltd. Methods of detection GPVI
HUE026953T2 (en) * 2007-06-01 2016-08-29 Univ Maryland Immunoglobulin constant region fc receptor binding agents
CN102026659A (zh) * 2008-04-22 2011-04-20 Csl百灵有限公司 通过抑制gpvi预防和治疗癌症的方法
US8889645B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8889646B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8318923B2 (en) 2009-06-03 2012-11-27 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
JP5699078B2 (ja) 2009-07-30 2015-04-08 富士フイルム株式会社 遺伝子組み換えゼラチンを含む腎臓イメージング剤
CA2784498A1 (fr) 2009-12-18 2011-06-23 Sanofi Nouveaux anticorps antagonistes et leurs fragments fab diriges contre gpvi, et utilisations de ceux-ci
EP2397495A1 (fr) * 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2336188A1 (fr) * 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
US10468565B2 (en) 2012-06-11 2019-11-05 Cree, Inc. LED package with multiple element light source and encapsulant having curved and/or planar surfaces
AU2013305885B2 (en) 2012-08-20 2017-12-21 Gliknik Inc. Molecules with antigen binding and polyvalent Fc gamma receptor binding activity
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
CA3026420A1 (fr) 2016-06-07 2017-12-14 Gliknik Inc. Stradomeres optimises par la cysteine
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
EP3551227A4 (fr) 2016-12-09 2020-07-29 Gliknik Inc. Méthodes de traitement de troubles inflammatoires avec des composés fc multivalents
CN108918564B (zh) * 2018-08-09 2021-02-02 陕西延长石油(集团)有限责任公司研究院 一种适用于泥页岩矿物成分定量的分析方法
CN111134760B (zh) * 2020-02-18 2024-09-13 绵竹市人民医院 一种介入微创手术切口按压止血设备

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080968A1 (fr) * 2001-04-09 2002-10-17 Millennium Pharmaceuticals, Inc. Glycoproteine vi et utilisations de cette derniere
WO2003008454A2 (fr) * 2001-07-18 2003-01-30 Merck Patent Gmbh Proteine de fusion, glycoproteine vi
WO2003104282A2 (fr) * 2002-06-07 2003-12-18 Procorde Gmbh Immunoadhesine comprenant un domaine de glycoproteine vi
WO2005007674A2 (fr) * 2003-07-11 2005-01-27 Molecular Innovations Anticorps anti-vitronectine humaine et methodes de fabrication de celui-ci
WO2005054294A2 (fr) * 2003-12-03 2005-06-16 Trigen Gmbh Inhibiteurs d'une glycoproteine vi a base d'un anticorps monoclonal hgp 5c4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080968A1 (fr) * 2001-04-09 2002-10-17 Millennium Pharmaceuticals, Inc. Glycoproteine vi et utilisations de cette derniere
WO2003008454A2 (fr) * 2001-07-18 2003-01-30 Merck Patent Gmbh Proteine de fusion, glycoproteine vi
WO2003104282A2 (fr) * 2002-06-07 2003-12-18 Procorde Gmbh Immunoadhesine comprenant un domaine de glycoproteine vi
WO2005007674A2 (fr) * 2003-07-11 2005-01-27 Molecular Innovations Anticorps anti-vitronectine humaine et methodes de fabrication de celui-ci
WO2005054294A2 (fr) * 2003-12-03 2005-06-16 Trigen Gmbh Inhibiteurs d'une glycoproteine vi a base d'un anticorps monoclonal hgp 5c4

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CIERNIEWSKI C ET AL: "Anti-(Arg-Gly-Asp-Ser) antibody and its interaction with fibronectin, fibrinogen and platelets", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 177, no. 1, October 1988 (1988-10-01), pages 109 - 115, XP002099824, ISSN: 0014-2956 *
GRÜNER S ET AL: "Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 105, no. 4, 15 February 2005 (2005-02-15), pages 1492 - 1499, XP002375721, ISSN: 0006-4971 *
SCHULZ CHRISTIAN ET AL: "Glycoprotein VI mediates platelet adhesion to endothelial cells in vivo", CIRCULATION, vol. 112, no. 17, Suppl. S, October 2005 (2005-10-01), & 78TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 13 -16, 2005, pages U93, XP009067061, ISSN: 0009-7322 *
SMETHURST PETER A ET AL: "Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody.", BLOOD, vol. 103, no. 3, 1 February 2004 (2004-02-01), pages 903 - 911, XP002383117, ISSN: 0006-4971 *
WU YA-PING ET AL: "Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.", BLOOD. 15 AUG 2004, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1034 - 1041, XP002383118, ISSN: 0006-4971 *
YANG C H ET AL: "Inhibition of RPE cell-mediated matrix adhesion and collagen gel contraction by crovidisin, a collagen-binding snake venom protein.", CURRENT EYE RESEARCH. NOV 1997, vol. 16, no. 11, November 1997 (1997-11-01), pages 1119 - 1126, XP009067064, ISSN: 0271-3683 *

Also Published As

Publication number Publication date
WO2006061650A2 (fr) 2006-06-15
EP1824979A2 (fr) 2007-08-29

Similar Documents

Publication Publication Date Title
WO2006061650A3 (fr) Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
CA2726087A1 (fr) Immunoglobulines a deux domaines variables et leurs utilisations
WO2006023544A3 (fr) Applications therapeutiques d'inhibiteurs de rtp801
WO2007117381A3 (fr) Activateurs de glucokinase
WO2007005879A3 (fr) Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
EP3050876A3 (fr) Modulateurs de kinase
WO2009134776A3 (fr) Immunoglobulines à double domaine variable et utilisations
WO2009149185A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2007040650A3 (fr) Promoteurs d'apoptose
WO2006099111A3 (fr) Reducteurs d'anevrismes
WO2007053189A3 (fr) Compositions et méthodes pour altérer une fonction immunitaire
WO2007141796A3 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801l
ATE473636T1 (de) Nahrungsmittel mit probiotischem und isoliertem beta-glukan und verwendungsverfahren dafür
WO2018042438A3 (fr) Produits dérivés du sang humain à activité fibrinolytique réduite et leurs utilisations dans des troubles hémostatiques
WO2009021708A3 (fr) Modulation par des immunoglobulines intraveineuses (ivig) de chimiokines pour le traitement de la sclérose en plaques, de la maladie d'alzheimer et de la maladie de parkinson
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2007084684A3 (fr) Utilisations therapeutiques d’inhibiteurs de rtp801
WO2008003943A3 (fr) Inhibition d'agrégation d'alpha-synucléine
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
WO2007135571A3 (fr) Antigènes de groupes sanguins de types différents pour applications diagnostiques et thérapeutiques
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
WO2008127654A3 (fr) Procédés et compositions pour protéines de coagulation intra-articulaires
WO2003001968A8 (fr) Compositions et procedes prohibant l'activation plaquettaire et la thrombose
WO2006122046A3 (fr) Therapies pour maladies vasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005849048

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005849048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11792857

Country of ref document: US